Var Ruchi Sharma, Girish Kumar Gupta, A. K. Sharma, Navneet Batra, Daljit K. Sharma, Amit Joshi and Anil K. Sharma* Pages 1633 - 1638 ( 6 )
Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge.
Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.PI3K/Akt/mTOR, breast cancer, cell proliferation, intracellular, cytotoxic, therapy.
Department of Biotechnology, Maharishi Markandeshwar University, Mullana-Ambala (Haryana), Department of Pharmaceutical Chemistry, M.M. College of Pharmacy, Maharishi Markandeshwar University, Mullana-Ambala (Haryana), Department of Physics, Maharishi Markandeshwar University, Mullana-Ambala (Haryana), Department of Biotechnology, GGDSD College, Sec 32 Chandigarh, Deparment of Science, Gurukul Global School, Chandigarh, Department of Biotechnology & Bioinformatics, SGGS College, Sector 26 Chandigarh, Department of Biotechnology, M.M. University, Mullana-Ambala -133207, Haryana